AlphaValue Corporate Services
COVERAGE ABOUT US CONTACT FR
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR 		Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 438%
Price (€) 2.13
Target Price (€) 11.5
Market Cap (€M) 77.8
Perf. 1W: 13.9%
Perf. 1M: -37.7%
Perf. 3M: -60.2%
Perf Ytd: -57.1%
10 day relative perf. to stoxx600: -4.87%
20 day relative perf. to stoxx600: -37.4%
EPS change05/09/2022
Download

Adjusting our forecasts to the new number of shares
Change in EPS2022 : € -0.23 vs -0.26ns
2023 : € -0.25 vs -0.31ns

We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022. As a result, the loss per share for FY22/23 decreases.
Change in NAV€ 12.3 vs 13.3-7.88%

We have adjusted our numbers to the current number of shares (after the exercise of subscription rights) which now stands at 34.83m as of August 2022.
Change in DCF€ 13.3 vs 14.6-9.05%

We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022.
Updates
.